All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Anifrolumab, a type I interferon receptor 1 (IFNAR1) is approved for treatment of adults with moderate to severe systemic lupus erythematosus (SLE). It acts by blocking type I interferon (IFN) signaling that plays a key role in the pathogenesis of SLE.
Below, we summarize an article published by Baker et al. in Annals of the Rheumatic Diseases investigating the immunomodulatory mechanisms underlying IFNAR1 blockade by anifrolumab using longitudinal transcriptomic and proteomic analyses of the phase III TULIP-1 and TULIP-2 trials.
Figure 1. Most significantly downregulated genes by anifrolumab vs placebo*
*Data from Baker, et al.1
Key learnings |
|
Subscribe to get the best content related to lupus delivered to your inbox